倍他司汀：议程上有什么新内容？
Betahistine: what's new on the agenda?
作者信息
Barak Nir
机构信息
CSO-Obecure Ltd, Paz Towers, 5 Shoham St, Ramat Gan, 52121, Israel.
出版信息
Expert Opin Investig Drugs. 2008 May;17(5):795-804. doi: 10.1517/13543784.17.5.795.
BACKGROUND
Betahistine is an orally administered, centrally acting histamine H(1) receptor agonist with partial H(3) antagonistic activity and no H(2)-binding effects. In the past betahistine was clinically studied mainly as a vasodilator for conditions such as cluster headaches, vascular dementia and Meniere's disease, for which it is still used. In recent years, histamine was found to be a key neurotransmitter in the regulation of feeding behavior.
OBJECTIVE
To provide a review of the developmental history and current research interests of betahistine.
METHODS
All reports of betahistine use in animals and humans were retrieved and reviewed.
RESULTS/CONCLUSION: The unique pharmacologic properties of betahistine point to its potential future use as an antiobesity agent.
背景
倍他司汀是一种口服的、作用于中枢的组胺H(1)受体激动剂，具有部分H(3)拮抗活性，无H(2)结合效应。过去，倍他司汀主要作为血管扩张剂用于丛集性头痛、血管性痴呆和梅尼埃病等病症的临床研究，目前仍在使用。近年来，组胺被发现是调节进食行为的关键神经递质。
目的
综述倍他司汀的发展历程及当前的研究热点。
方法
检索并回顾了所有关于倍他司汀在动物和人类中的应用报告。
结果/结论：倍他司汀独特的药理特性表明其未来有可能用作抗肥胖药物。
Zotero 插件